BioStock publishes article after Prolight signed supply agreement with BRAINBox valued at USD 3.9 million
BioStock publishes article after Prolight Diagnostics signed supply agreement with BRAINBox valued at USD 3.9 million during the first year, with comments from Prolight. Read the full article here: https://biostock.se/en/2026/09/prolight-comments-on-usd-3-9m-brainbox-deal/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics develops Psyros®, a groundbreaking Point-of-Care platform for highly sensitive […]
Prolight signs supply agreement with BRAINBox valued at USD 3.9 million for the first year
Prolight Diagnostics AB (publ), pioneer in digital point of care testing, today announced that it has signed a supply agreement with BRAINBox Solutions for instruments and cartridges. Anticipated first year supply post FDA clearance and market launch is valued at USD 3.9 million (approximately SEK 37 million). The agreement supports the commercialisation of BRAINBox’s traumatic […]
Prolight Diagnostics publishes half-year report, 2026
Financial overview Second quarter, April 1 – June 30, Q2 2026(Figures in parentheses refer to the corresponding period in the previous year.)· Net sales amounted to 0 (0).· Other operating income amounted to 2,840 (13,945) thousand SEK.· Operating profit (EBIT) amounted to -8,304 (-15,346) thousand SEK.· Profit after tax amounted to -8,304 (-12,740) thousand SEK.· Earnings per share before and […]
Prolight signs GBP 2.24m development agreement with BRAINBox
Prolight Diagnostics today announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions. The agreement generates revenues of approximately GBP 2.24 million (SEK 29 million) of which GBP 2,09 million (SEK 27 million) is to be recognized during the second half of 2026. In the feasibility […]
Prolight receives Notice of Allowance for Psyros® patent in the US
Prolight Diagnostics today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance relating to a patent application covering key aspects of the Psyros® single-molecule-counting technology. This is expected to become the first granted U.S. patent relating to the Psyros platform. The patent application (US application No. 18/267,726) covers methods to extend […]
Prolight Diagnostics publishes quarterly report Q1, 2026
First quarter, January 1 – March 31, 2026 Net sales amounted to 0 (0). Other operating income amounted to 1,201 (1,662) thousand SEK. Operating profit (EBIT) amounted to -10,389 (10,937) thousand SEK. Profit after tax amounted to -10,389 (-10,937) thousand SEK. Earnings per share before and after dilution: -0.86 (-1.55) SEK. Cash flow from operating activities was -12,640 (-9,176) thousand SEK. […]
Annual general meeting of Prolight Diagnostics AB (publ) on 26 May 2026
The annual general meeting (AGM) of Prolight Diagnostics AB (publ) took place on 26 May 2026 in Stockholm. Full information regarding the decisions of the AGM is available on the company’s website, www.prolightdx.com. The AGM resolved in accordance with all of the motions presented in the notification of the AGM except for the election of […]
Prolight Diagnostics AB (publ) publishes annual report for 2025
Prolight Diagnostics AB (publ) has today published its Annual Report for the financial year 2025. The report is available via the attached file or on the Company’s website: https://prolightdx.com/en/investors/financial-reports/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, […]
Prolight Diagnostics achieves design freeze for Psyros® instrument
Prolight Diagnostics today announces that it has achieved formal design freeze of the instrument for the Psyros platform, a key milestone toward clinical development and scalable manufacturing. “Achieving instrument design freeze is a large and decisive step forward. The final design supports scalable manufacturing and reliable performance in demanding clinical environments such as ambulances and […]
Prolight secures second patent in Japan for Psyros® technology
Prolight Diagnostics announces today that the Japan Patent Office, JPO has issued an official Decision to Grant notification for a second patent application relating to the Psyros single-molecule-counting technology. The official legal notification was dated the 24th of April 2026. “Securing a second patent in Japan represents an important milestone and further strengthens our intellectual property position in a strategically important market. The patent demonstrates the […]